Anti-Human CDC123 Monoclonal Antibody (1A549) from ProteoGenix; catalogue ARO-A23317; research use only.
Know who made it. See the evidence. Buy through one marketplace.
A powerful tool for biotech research and discovery. This highly specific antibody targets the CDC123 protein, a key player in cell division and proliferation. With its exceptional binding affinity and selectivity, this antibody is a valuable addition to any biotech laboratory.
The biological function of the Anti-Human CDC123 Monoclonal Antibody (1A549) is to inhibit the activity of the CDC123 protein, leading to cell cycle arrest and ultimately, cell death. This makes it a valuable tool for studying the role of CDC123 in various cellular processes, including cancer development and progression.
One of the main applications of this antibody is in cancer research. By targeting the CDC123 protein, researchers can gain valuable insights into the mechanisms of tumor growth and identify potential therapeutic targets. This antibody has also been shown to be effective in inhibiting the growth of cancer cells in pre-clinical studies, making it a promising candidate for future cancer treatments.
In addition to cancer research, the Anti-Human CDC123 Monoclonal Antibody (1A549) has also been used in other experimental settings. It has been shown to be effective in studying the role of CDC123 in cell division and proliferation, making it a valuable tool for understanding fundamental cellular processes.
The Anti-Human CDC123 Monoclonal Antibody (1A549) has been rigorously tested and validated for use in various experimental techniques, including Western blotting, immunofluorescence, and immunohistochemistry. Its high specificity and sensitivity ensure reliable and reproducible results, making it a trusted choice for researchers.
In summary, the Anti-Human CDC123 Monoclonal Antibody (1A549) is a valuable tool for biotech research, particularly in cancer studies. Its ability to target and inhibit the CDC123 protein makes it a powerful tool for understanding cellular processes and identifying potential therapeutic targets. Trust in its specificity and sensitivity for reliable results in a variety of experimental techniques. Order now and take your research to the next level.
ProteoGenix catalogue number ARO-A23317. For research use only.
Target: Translation initiation factor eIF2 assembly protein, Cell division cycle protein 123 homolog, Protein D123, HT-1080, PZ32, CDC123; Clonality: Monoclonal Antibody; Reactivity: Human; Applications: ELISA, IHC.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| Human |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
